research use only

Bictegravir Integrase inhibitor

Cat.No.S5911

Bictegravir (GS-9883) is a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase.
Jump to

Quality Control

Batch: Purity: 99.93%
99.93

Solubility

In vitro
Batch:

DMSO : 90 mg/mL (200.27 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 449.38 Formula

C21H18F3N3O5

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 1611493-60-7 -- Storage of Stock Solutions

Synonyms GS-9883 SMILES C1CC2CC1N3C(O2)CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC50/Ki
HIV-1 integrase
In vitro
Bictegravir exhibits potent and selective in vitro antiretroviral activity in both T-cell lines and primary human T lymphocytes, with 50% effective concentrations ranging from 1.5 to 2.4 nM and selectivity indices up to 8,700 relative to cytotoxicity. This compound inhibits the strand transfer activity with an IC50 of 7.5 ± 0.3 nM. Relative to its inhibition of strand transfer activity, it is a much weaker inhibitor of 3'-processing activity of HIV-1 integrase, with an IC50 of 241 ± 51 nM. This chemical potently inhibits HIV-1 replication in both MT-2 and MT-4 cells with EC50s of 1.5 and 2.4 nM, respectively, and selectivity indices (50% cytotoxic concentration [CC50]/EC50) of ∼6,800 in MT-2 cells and ∼1,500 in MT-4 cells.
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-14)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07708727 RECRUITING
HIV-1-infection
Gilead Sciences
2026-07-29 PHASE2; PHASE3
NCT06532656 ACTIVE_NOT_RECRUITING
HIV-1-infection
Gilead Sciences
2024-11-20 PHASE2; PHASE3
NCT07266831 RECRUITING
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC
2025-12-18 PHASE2; PHASE3
NCT07055451 ACTIVE_NOT_RECRUITING
HIV-1-infection
Gilead Sciences
2025-08-12 PHASE1
NCT06544733 ACTIVE_NOT_RECRUITING
HIV-1-Infection
Gilead Sciences
2024-08-20 PHASE2; PHASE3
NCT06891066 ACTIVE_NOT_RECRUITING
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Merck Sharp & Dohme LLC
2025-04-14 PHASE2

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Signaling Pathway Map